WO2018183354A1 - Niraparib compositions - Google Patents
Niraparib compositions Download PDFInfo
- Publication number
- WO2018183354A1 WO2018183354A1 PCT/US2018/024603 US2018024603W WO2018183354A1 WO 2018183354 A1 WO2018183354 A1 WO 2018183354A1 US 2018024603 W US2018024603 W US 2018024603W WO 2018183354 A1 WO2018183354 A1 WO 2018183354A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- indazole
- piperidin
- carboxamide
- phenyl
- Prior art date
Links
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title claims abstract description 396
- 239000000203 mixture Substances 0.000 title claims abstract description 305
- 229950011068 niraparib Drugs 0.000 title abstract description 221
- 238000000034 method Methods 0.000 claims description 64
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims description 45
- 238000002441 X-ray diffraction Methods 0.000 claims description 44
- 239000003960 organic solvent Substances 0.000 claims description 37
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 36
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 36
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical group CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 36
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 26
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 24
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 21
- 239000002904 solvent Substances 0.000 claims description 20
- 238000001179 sorption measurement Methods 0.000 claims description 20
- 239000002775 capsule Substances 0.000 claims description 16
- 238000007707 calorimetry Methods 0.000 claims description 14
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 12
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 235000019253 formic acid Nutrition 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000006186 oral dosage form Substances 0.000 claims description 9
- 238000004566 IR spectroscopy Methods 0.000 claims description 7
- 238000001069 Raman spectroscopy Methods 0.000 claims description 7
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 239000003880 polar aprotic solvent Substances 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 6
- 239000003586 protic polar solvent Substances 0.000 claims description 6
- 239000002274 desiccant Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 abstract description 18
- 150000001875 compounds Chemical class 0.000 abstract description 15
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 62
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 47
- 229960001021 lactose monohydrate Drugs 0.000 description 47
- 239000000945 filler Substances 0.000 description 38
- 230000002354 daily effect Effects 0.000 description 33
- 235000019359 magnesium stearate Nutrition 0.000 description 31
- 206010028980 Neoplasm Diseases 0.000 description 29
- 201000011510 cancer Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 239000000314 lubricant Substances 0.000 description 25
- 238000009472 formulation Methods 0.000 description 20
- 235000002639 sodium chloride Nutrition 0.000 description 20
- 239000007909 solid dosage form Substances 0.000 description 19
- 206010033128 Ovarian cancer Diseases 0.000 description 18
- 230000015556 catabolic process Effects 0.000 description 17
- 238000006731 degradation reaction Methods 0.000 description 17
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 16
- 239000003826 tablet Substances 0.000 description 16
- 239000008186 active pharmaceutical agent Substances 0.000 description 15
- -1 dextrates Chemical compound 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 150000004682 monohydrates Chemical group 0.000 description 13
- 230000000306 recurrent effect Effects 0.000 description 13
- 206010061535 Ovarian neoplasm Diseases 0.000 description 12
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 12
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 12
- 239000003814 drug Substances 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 11
- 208000035475 disorder Diseases 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 10
- 229920002472 Starch Polymers 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 9
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 9
- 229960001375 lactose Drugs 0.000 description 9
- 239000008101 lactose Substances 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- 206010005003 Bladder cancer Diseases 0.000 description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 239000003085 diluting agent Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 8
- 229910052697 platinum Inorganic materials 0.000 description 8
- 229940032147 starch Drugs 0.000 description 8
- 201000005112 urinary bladder cancer Diseases 0.000 description 8
- 201000001342 Fallopian tube cancer Diseases 0.000 description 7
- 208000013452 Fallopian tube neoplasm Diseases 0.000 description 7
- 208000026149 Primary peritoneal carcinoma Diseases 0.000 description 7
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 7
- 230000036961 partial effect Effects 0.000 description 7
- 230000037361 pathway Effects 0.000 description 7
- 238000011518 platinum-based chemotherapy Methods 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 239000000454 talc Substances 0.000 description 7
- 229910052623 talc Inorganic materials 0.000 description 7
- 229940033134 talc Drugs 0.000 description 7
- 235000012222 talc Nutrition 0.000 description 7
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 6
- 230000033616 DNA repair Effects 0.000 description 6
- 229930195725 Mannitol Natural products 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 6
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000000113 differential scanning calorimetry Methods 0.000 description 6
- 239000007884 disintegrant Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000000594 mannitol Substances 0.000 description 6
- 235000010355 mannitol Nutrition 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 239000000600 sorbitol Substances 0.000 description 6
- 235000010356 sorbitol Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 description 5
- 206010029260 Neuroblastoma Diseases 0.000 description 5
- 239000012661 PARP inhibitor Substances 0.000 description 5
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 5
- 206010060862 Prostate cancer Diseases 0.000 description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 5
- 206010039491 Sarcoma Diseases 0.000 description 5
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 235000021355 Stearic acid Nutrition 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000001913 cellulose Substances 0.000 description 5
- 229940096516 dextrates Drugs 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 208000005017 glioblastoma Diseases 0.000 description 5
- 229940049654 glyceryl behenate Drugs 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 5
- 229920001983 poloxamer Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 235000010413 sodium alginate Nutrition 0.000 description 5
- 239000000661 sodium alginate Substances 0.000 description 5
- 229940005550 sodium alginate Drugs 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 239000008117 stearic acid Substances 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- 206010005949 Bone cancer Diseases 0.000 description 4
- 208000018084 Bone neoplasm Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
- 206010014733 Endometrial cancer Diseases 0.000 description 4
- 206010014759 Endometrial neoplasm Diseases 0.000 description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 4
- 206010023347 Keratoacanthoma Diseases 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 description 4
- 206010038389 Renal cancer Diseases 0.000 description 4
- 201000010208 Seminoma Diseases 0.000 description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 206010057644 Testis cancer Diseases 0.000 description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 201000000220 brain stem cancer Diseases 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 201000007455 central nervous system cancer Diseases 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000008121 dextrose Substances 0.000 description 4
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 201000004101 esophageal cancer Diseases 0.000 description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 210000004602 germ cell Anatomy 0.000 description 4
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 4
- 201000010536 head and neck cancer Diseases 0.000 description 4
- 208000014829 head and neck neoplasm Diseases 0.000 description 4
- 201000010982 kidney cancer Diseases 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 201000002120 neuroendocrine carcinoma Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 229960000502 poloxamer Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 206010038038 rectal cancer Diseases 0.000 description 4
- 201000001275 rectum cancer Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 201000006402 rhabdoid cancer Diseases 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- 235000010234 sodium benzoate Nutrition 0.000 description 4
- 239000004299 sodium benzoate Substances 0.000 description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 4
- 229960002920 sorbitol Drugs 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 201000003120 testicular cancer Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 201000002510 thyroid cancer Diseases 0.000 description 4
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
- 239000005995 Aluminium silicate Substances 0.000 description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 3
- 102000052609 BRCA2 Human genes 0.000 description 3
- 108700020462 BRCA2 Proteins 0.000 description 3
- 101150008921 Brca2 gene Proteins 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000017604 Hodgkin disease Diseases 0.000 description 3
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 3
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 229920001100 Polydextrose Polymers 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 235000012211 aluminium silicate Nutrition 0.000 description 3
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 239000008116 calcium stearate Substances 0.000 description 3
- 229940078456 calcium stearate Drugs 0.000 description 3
- 235000011132 calcium sulphate Nutrition 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 3
- 239000000832 lactitol Substances 0.000 description 3
- 235000010448 lactitol Nutrition 0.000 description 3
- 229960003451 lactitol Drugs 0.000 description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 3
- 206010024627 liposarcoma Diseases 0.000 description 3
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- 229960001855 mannitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- 201000008968 osteosarcoma Diseases 0.000 description 3
- 235000013856 polydextrose Nutrition 0.000 description 3
- 239000001259 polydextrose Substances 0.000 description 3
- 229940035035 polydextrose Drugs 0.000 description 3
- 238000009097 single-agent therapy Methods 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N 2-stearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 229920004482 WACKER® Polymers 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 2
- 229960000878 docusate sodium Drugs 0.000 description 2
- 230000005782 double-strand break Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088679 drug related substance Drugs 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000002563 ionic surfactant Substances 0.000 description 2
- 231100000225 lethality Toxicity 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000008185 minitablet Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960000540 polacrilin potassium Drugs 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 2
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940083037 simethicone Drugs 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 229960002668 sodium chloride Drugs 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940074410 trehalose Drugs 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- DMBUODUULYCPAK-UHFFFAOYSA-N 1,3-bis(docosanoyloxy)propan-2-yl docosanoate Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC DMBUODUULYCPAK-UHFFFAOYSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WCOXQTXVACYMLM-UHFFFAOYSA-N 2,3-bis(12-hydroxyoctadecanoyloxy)propyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC(O)CCCCCC)COC(=O)CCCCCCCCCCC(O)CCCCCC WCOXQTXVACYMLM-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- LCPFHXWLJMNKNC-PFEQFJNWSA-N 4-methylbenzenesulfonate;2-[4-[(3s)-piperidin-1-ium-3-yl]phenyl]indazole-7-carboxamide Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1 LCPFHXWLJMNKNC-PFEQFJNWSA-N 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000008271 Atypical teratoid rhabdoid tumor Diseases 0.000 description 1
- 108700010154 BRCA2 Genes Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101100407084 Caenorhabditis elegans parp-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 235000013913 Ceratonia Nutrition 0.000 description 1
- 241001060815 Ceratonia Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000004139 Choroid Plexus Neoplasms Diseases 0.000 description 1
- 208000037156 Choroid plexus tumor Diseases 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 206010059352 Desmoid tumour Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000019886 MethocelTM Nutrition 0.000 description 1
- 101100382264 Mus musculus Ca14 gene Proteins 0.000 description 1
- 101100112373 Mus musculus Ctsm gene Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- BSXXLRNUYGZGBW-UHFFFAOYSA-N O.CC1=CC=C(C=C1)S(=O)(=O)O.N=1NC=C2C=CC=C(C12)C(=O)N Chemical compound O.CC1=CC=C(C=C1)S(=O)(=O)O.N=1NC=C2C=CC=C(C12)C(=O)N BSXXLRNUYGZGBW-UHFFFAOYSA-N 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 201000007286 Pilocytic astrocytoma Diseases 0.000 description 1
- 229920002266 Pluriol® Polymers 0.000 description 1
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 229920000148 Polycarbophil calcium Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010039019 Rhabdoid tumour of the kidney Diseases 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 101100094962 Salmo salar salarin gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- SZYSLWCAWVWFLT-UTGHZIEOSA-N [(2s,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)-2-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxolan-2-yl]methyl octadecanoate Chemical compound O([C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@]1(COC(=O)CCCCCCCCCCCCCCCCC)O[C@H](CO)[C@@H](O)[C@@H]1O SZYSLWCAWVWFLT-UTGHZIEOSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- SPTSIOTYTJZTOG-UHFFFAOYSA-N acetic acid;octadecanoic acid Chemical compound CC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O SPTSIOTYTJZTOG-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 235000010407 ammonium alginate Nutrition 0.000 description 1
- 239000000728 ammonium alginate Substances 0.000 description 1
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033590 base-excision repair Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000000227 bioadhesive Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 239000001175 calcium sulphate Substances 0.000 description 1
- UBWYRXFZPXBISJ-UHFFFAOYSA-L calcium;2-hydroxypropanoate;trihydrate Chemical compound O.O.O.[Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O UBWYRXFZPXBISJ-UHFFFAOYSA-L 0.000 description 1
- ZHZFKLKREFECML-UHFFFAOYSA-L calcium;sulfate;hydrate Chemical compound O.[Ca+2].[O-]S([O-])(=O)=O ZHZFKLKREFECML-UHFFFAOYSA-L 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- LDVVMCZRFWMZSG-UHFFFAOYSA-N captan Chemical compound C1C=CCC2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C21 LDVVMCZRFWMZSG-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940043431 ceratonia Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229920001429 chelating resin Polymers 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 201000006827 desmoid tumor Diseases 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 229960000829 kaolin Drugs 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007942 layered tablet Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 235000005772 leucine Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030173 low grade glioma Diseases 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 229960000869 magnesium oxide Drugs 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000007912 modified release tablet Substances 0.000 description 1
- 230000003232 mucoadhesive effect Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008180 pharmaceutical surfactant Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229950005134 polycarbophil Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 208000013860 rhabdoid tumor of the kidney Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000033443 single strand break repair Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical class [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940097346 sulfobutylether-beta-cyclodextrin Drugs 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229940057977 zinc stearate Drugs 0.000 description 1
- 239000002888 zwitterionic surfactant Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- Niraparib is an orally active and potent poly (ADP-ribose) polymerase, or PARP, inhibitor.
- Niraparib and pharmaceutically acceptable salts thereof are disclosed in International Publication No. WO2007/113596 and European Patent No. EP2007733B 1; International Publication No.
- PARP is a family of proteins involved in many functions in a cell, including DNA repair, gene expression, cell cycle control, intracellular trafficking and energy metabolism. PARP proteins play key roles in single strand break repair through the base excision repair pathway. PARP inhibitors have shown activity as a monotherapy against tumors with existing DNA repair defects, such as BRCAl and BRCA2, and as a combination therapy when administered together with anticancer agents that induce DNA damage.
- One embodiment provides a composition comprising crystalline Form I of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Another embodiment provides the composition wherein the crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- compositions where the crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide is characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 9.5 ⁇ 0.2, 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 24.9 ⁇ 0.2, 25.6 ⁇ 0.2, 26.0 ⁇ 0.2, and 26.9 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by X-ray diffraction pattern reflections at 2 ⁇ values of 9.5 ⁇ 0.2 and 26.0 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by X-ray diffraction pattern reflections at 2 ⁇ values of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- compositions wherein the crystalline Form I are characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by at least two X-ray diffraction pattern reflections selected from a 2 ⁇ value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- compositions wherein the crystalline Form I is characterized by at least three X-ray diffraction pattern reflections selected from a 2 ⁇ value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by at least four X-ray diffraction pattern reflections selected from a 20 value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- compositions wherein the crystalline Form I are characterized by a scanning differential calorimetry pattern substantially as shown in Figure 2.
- Another embodiment provides the composition wherein the crystalline Form I is characterized by a Raman spectroscopy pattern substantially as shown in Figure 3.
- Another embodiment provides the composition wherein the crystalline Form I is characterized by an infrared spectroscopy pattern substantially as shown in Figure 4.
- Another embodiment provides the composition wherein the crystalline Form I is characterized by a dynamic water vapor sorption pattern substantially as shown in Figure 5.
- compositions wherein substantially free of Form II and Form III means less than about 20% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- composition wherein substantially free of Form II and Form III means less than about 15% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- substantially free of Form II and Form III means less than about 10% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- composition wherein substantially free of Form II and Form III means less than about 8% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- composition wherein substantially free of Form II and Form III means less than about 6% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- compositions wherein substantially free of Form II and Form III means less than about 4% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- composition wherein substantially free of Form II and Form III means less than about 3% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- composition wherein substantially free of Form II and Form III means less than about 2% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- composition wherein substantially free of Form II and Form III means less than about 1% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- One embodiment provides a composition comprising crystalline Form II of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4- [(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- One embodiment provides a composition comprising crystalline Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide.
- One embodiment provides a composition comprising crystalline Form II 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline Form III of 2- ⁇ 4-[(3S)-piperidin- 3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- crystalline Form II is characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 9.7 ⁇ 0.3, 12.8 ⁇ 0.3, 17.9 ⁇ 0.3, 19.7 ⁇ 0.3, and 21.8 ⁇ 0.3.
- crystalline Form II has an X-ray powder diffraction pattern substantially as shown in Figure 9 for Form II.
- One embodiment provides a composition comprising crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4- [(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline Form II of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- One embodiment provides a composition comprising crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide.
- One embodiment provides crystalline Form III characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 17.8 ⁇ 0.2, 19.0 ⁇ 0.2, or 22.8 ⁇ 0.2.
- One embodiment provides crystalline Form III that has an X-ray powder diffraction pattern substantially as shown in Figure 9 for Form III.
- One embodiment provides crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide that has an X-ray powder diffraction pattern substantially as shown in Figure 7.
- One embodiment provides crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide characterized by a dynamic water vapor sorption pattern substantially as shown in Figure 8.
- One embodiment provides crystalline Form III of 2- ⁇ 4- [(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide characterized by a scanning differential calorimetry pattern substantially as shown in Figure 2.
- One embodiment provides a method of making crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide, comprising dissolving a composition comprising Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide or Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide, or a mixture thereof, in a solvent having a water: organic solvent ratio of about 10: 1 to about 400: 1 (v/v), and crystallizing the crystalline Form I.
- Another embodiment provides the method wherein the water: organic solvent ratio is about 10: 1 (v/v), about 50: 1 (v/v), about 100: 1 (v/v), about 200: 1 (v/v), about 300: 1 (v/v), or about 400: 1 (v/v).
- the organic solvent is a polar solvent, a polar protic solvent, a polar aprotic solvent, an ether-containing solvent, or any combination thereof.
- compositions wherein the organic solvent is 2-propanol, acetone, methyl ethyl ketone, acetonitrile, acetic acid, formic acid, methyl tert-butyl ether, dioxane, dimethyl sulfoxide, or any combination thereof.
- the organic solvent is acetone, methyl ethyl ketone, acetonitrile, methyl tert- butyl ether, dioxane, dimethyl sulfoxide, or any combination thereof.
- Another embodiment provides the composition wherein the organic solvent is 2-propanol, acetic acid, formic acid, or any combination thereof.
- composition wherein the organic solvent and water is heated prior to crystallization.
- One embodiment provides a composition comprising crystalline Form I of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide prepared by dissolving a composition comprising Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide or Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide, or a mixture thereof, in a solvent having a water: organic solvent ratio of about 10: 1 to about 400: 1 (v/v), and crystallizing the crystalline Form I.
- compositions wherein the water: organic solvent ratio is about 10: 1 (v/v), about 50: 1 (v/v), about 100: 1 (v/v), about 200: 1 (v/v), about 300: 1 (v/v), or about 400: 1 (v/v).
- organic solvent is a polar solvent, a polar protic solvent, a polar aprotic solvent, an ether-containing solvent, or any combination thereof.
- compositions wherein the organic solvent is 2-propanol, acetone, methyl ethyl ketone, acetonitrile, acetic acid, formic acid, methyl tert-butyl ether, dioxane, dimethyl sulfoxide, or any combination thereof.
- the organic solvent is acetone, methyl ethyl ketone, acetonitrile, methyl tert- butyl ether, dioxane, dimethyl sulfoxide, or any combination thereof.
- Another embodiment provides the composition wherein the organic solvent is 2-propanol, acetic acid, formic acid, or any combination thereof.
- composition wherein the organic solvent and water is heated prior to crystallization.
- a composition described herein is a pharmaceutical composition (e.g., a pharmaceutical composition comprising at least one pharmaceutically acceptable excipient).
- a pharmaceutical composition comprising crystalline Form I of 2- ⁇ 4-[(3 S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide, and at least one pharmaceutically acceptable excipient.
- Another embodiment provides the pharmaceutical composition wherein the composition is in an oral dosage form.
- Another embodiment provides the pharmaceutical composition wherein the oral dosage form is a tablet or capsule.
- One embodiment provides an article of manufacture comprising multiple unit doses of the pharmaceutical composition in a sealed container with written instructions for use.
- the article of manufacture comprising multiple unit doses of the pharmaceutical composition in a sealed container with written instructions for use further comprises an induction seal, desiccant, or any combination thereof.
- One embodiment provides a method for treating cancer in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3 S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide, and at least one pharmaceutically acceptable excipient, wherein the cancer is selected from the group consisting of ovarian cancer, breast cancer, cervical cancer, endometrial cancer, prostate cancer, testicular cancer, pancreatic cancer, esophageal cancer, head and neck cancer, gastric cancer, bladder cancer, lung cancer, bone cancer, colon cancer, rectal cancer, thyroid cancer, brain and central nervous system cancers, glioblastoma, neuroblastoma, neuroendocrine cancer, rhabdoid cancer, keratoacanthoma
- One embodiment provides a method for treating cancer in a patient having been diagnosed with cancer comprising administering to said patient a therapeutically effective amount of the pharmaceutical comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3 S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide, and at least one pharmaceutically acceptable excipient, wherein the cancer is selected from the group consisting of ovarian cancer, breast cancer, cervical cancer, endometrial cancer, prostate cancer, testicular cancer, pancreatic cancer, esophageal cancer, head and neck cancer, gastric cancer, bladder cancer, lung cancer, bone cancer, colon cancer, rectal cancer, thyroid cancer, brain and central nervous system cancers, glioblastoma, neuroblastoma, neuroendocrine cancer, rhabdoid cancer, keratoacanthom
- Another embodiment provides the method wherein the cancer is selected from the group consisting of ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and combinations thereof. Another embodiment provides the method wherein the cancer is a recurrent cancer. Another embodiment provides the method wherein the subject is a human subject. Another embodiment provides the method wherein the human subject was previously treated with a chemotherapy. Another
- the chemotherapy is a platinum-based chemotherapy.
- Another embodiment provides the method wherein the human subject had a complete or partial response to the chemotherapy.
- Another embodiment provides the method wherein the
- pharmaceutical composition is administered once per day, twice per day, three times per day, or four times per day. Another embodiment provides the method wherein the pharmaceutical composition is administered once per week, twice per week, three times per week, or four times per week. Another embodiment provides the method wherein the pharmaceutical composition is administered every other day. Another embodiment provides the method wherein the pharmaceutical composition is administered once per day. Another embodiment provides the method wherein the total dose of a the pharmaceutical composition administered within a 24 hour period is about 1 mg to about 1000 mg.
- Another embodiment provides the method wherein the total dose is about 1000 mg, about 900 mg, about 800 mg, about 700 mg, about 600 mg, about 500 mg, about 400 mg, about 300 mg, about 200 mg, about 100 mg, about 90 mg, about 80 mg, about 70 mg, about 60 mg, about 50 mg, about 40 mg, about 30 mg, about 20 mg, about 10 mg, about 5 mg, or about 1 mg.
- Another embodiment provides the method wherein the pharmaceutical composition is administered once per day and the total daily dose is about 300 mg.
- Another embodiment provides the method wherein the administration is oral administration.
- Fig. 1 shows an exemplary X-ray powder diffraction pattern for crystalline Form I of 2- ⁇ 4- [(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Fig. 2 shows an exemplary scanning differential calorimetry pattern for crystalline monohydrate Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline anhydrous Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Fig. 3 shows an exemplary Raman spectroscopy pattern for crystalline Form I of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Fig. 4 shows an exemplary infrared spectroscopy pattern for crystalline Form I of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Fig. 5 shows an exemplary dynamic water vapor sorption pattern for crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Fig. 6 shows an overlay of exemplary X-ray powder diffraction patterns for crystalline Form
- Fig. 7 shows an exemplary X-ray powder diffraction pattern for crystalline Form III of 2- ⁇ 4-
- Fig. 8 shows an exemplary dynamic water vapor sorption pattern for crystalline anhydrous Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Fig. 9 shows an overlay of exemplary X-ray powder diffraction patterns for crystalline Form I, Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- cancer includes both solid tumors and hematological malignancies.
- Cancers include, but are not limited to, ovarian cancer, breast cancer, cervical cancer, endometrial cancer, prostate cancer, testicular cancer, pancreatic cancer, esophageal cancer, head and neck cancer, gastric cancer, bladder cancer, lung cancer (e.g., adenocarcinoma, NSCLC and SCLC), bone cancer (e.g., osteosarcoma), colon cancer, rectal cancer, thyroid cancer, brain and central nervous system cancers, glioblastoma, neuroblastoma, neuroendocrine cancer, rhabdoid cancer, keratoacanthoma, epidermoid carcinoma, seminoma, melanoma, sarcoma (e.g., liposarcoma), bladder cancer, liver cancer (e.g., hepatocellular carcinoma), kidney cancer (e.g., renal cell carcinoma), myeloid disorders (e.g., AML, C
- composition as in pharmaceutical composition, is intended to encompass a drug product comprising niraparib or its pharmaceutically acceptable salts, esters, solvates, polymorphs, stereoisomers or mixtures thereof, and the other inert ingredient(s) (pharmaceutically acceptable excipients).
- pharmaceutical compositions are synonymous with “formulation” and “dosage form”.
- compositions of the invention include, but are not limited to, granules, tablets (single layered tablets, multilayered tablets, mini tablets, bioadhesive tablets, caplets, matrix tablets, tablet within a tablet, mucoadhesive tablets, modified release tablets, orally disintegrating tablets, pulsatile release tablets, timed release tablets, delayed release, controlled release, extended release and sustained release tablets), capsules (hard and soft or liquid filled soft gelatin capsules), pills, troches, sachets, powders, microcapsules, minitablets, tablets in capsules and microspheres, matrix composition and the like.
- the pharmaceutical composition refers to capsules.
- the pharmaceutical composition refers to hard gelatin capsules or HPMC based capsules.
- the pharmaceutical composition refers to hard gelatin capsules.
- “Diluents” increase bulk of the composition to facilitate compression or create sufficient bulk for homogenous blend for capsule filling.
- Such compounds include e.g., lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel®; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray- dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac® (Amstar); mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose-based diluents, confectioner's sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin;
- an “effective amount” or “therapeutically effective amount,” as used herein, refer to a sufficient amount of the niraparib being administered that would be expected to relieve to some extent one or more of the symptoms of the disease or condition being treated.
- the result of administration of niraparib disclosed herein is reduction and/or alleviation of the signs, symptoms, or causes of cancer.
- an “effective amount” for therapeutic uses is the amount of niraparib, including a formulation as disclosed herein required to provide a decrease or amelioration in disease symptoms without undue adverse side effects.
- therapeutically effective amount includes, for example, a prophylactically effective amount.
- an “an effective amount” or a “therapeutically effective amount” varies, in some embodiments, from subject to subject, due to variation in metabolism of the compound administered, age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician.
- the terms “enhance” or “enhancing” refers to an increase or prolongation of either the potency or duration of a desired effect of niraparib, or a diminution of any adverse symptomatology that is consequent upon the administration of the therapeutic agent.
- the term “enhancing” refers to the ability to increase or prolong, either in potency or duration, the effect of other therapeutic agents that are used in combination with niraparib disclosed herein.
- excipient means a pharmacologically inactive component such as a diluent, lubricant, surfactant, carrier, or the like. Excipients that are useful in preparing a pharmaceutical composition are generally safe, non-toxic and are acceptable for human pharmaceutical use.
- references to an excipient includes both one and more than one such excipient. Co-processed excipients are also covered under the scope of present invention.
- Filling agents include compounds such as lactose, lactose monohydrate, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starches, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
- Lubricants and “glidants” are compounds that prevent, reduce or inhibit adhesion or friction of materials.
- exemplary lubricants include, e.g., stearic acid, magnesium stearate, calcium hydroxide, talc, sodium stearyl fumarate, a hydrocarbon such as mineral oil, or hydrogenated vegetable oil such as hydrogenated soybean oil (Sterotex®), higher fatty acids and their alkali-metal and alkaline earth metal salts, such as aluminum, calcium, magnesium, zinc, stearic acid, sodium stearates, glycerol, talc, waxes, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, a polyethylene glycol (e.g., PEG-4000) or a methoxypolyethylene glycol such as CarbowaxTM, sodium oleate, sodium benzoate, glyceryl behenate, polyethylene glycol, magnesium or sodium la
- subject is used to mean an animal, preferably a mammal, including a human or non-human.
- patient and subject may be used interchangeably.
- a “therapeutically effective amount” or “effective amount” is that amount of a
- niraparib is an amount needed to achieve a desired pharmacologic effect or therapeutic improvement without undue adverse side effects.
- the effective amount of a niraparib will be selected by those skilled in the art depending on the particular patient and the disease. It is understood that “an effective amount” or a “therapeutically effective amount” can vary from subject to subject, due to variation in metabolism of niraparib, age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician.
- amelioration or lessening of the symptoms of a particular disease, disorder or condition by administration of a particular compound or pharmaceutical composition refers to any decrease of severity, delay in onset, slowing of progression, or shortening of duration, whether permanent or temporary, lasting or transient that is attributed to or associated with administration of the compound or composition.
- treat include alleviating, abating or ameliorating a disease or condition, for example cancer, symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, inhibiting the disease or condition, e.g., arresting the development of the disease or condition, relieving the disease or condition, causing regression of the disease or condition, relieving a condition caused by the disease or condition, or stopping the symptoms of the disease or condition either prophylactically and/or therapeutically.
- weight percent As used herein, “weight percent,” “wt %,” “percent by weight,” “% by weight,” and variations thereof refer to the concentration of a substance as the weight of that substance divided by the total weight of the composition and multiplied by 100.
- the present invention relates to solid dosage forms of niraparib and pharmaceutically acceptable salts thereof (e.g., niraparib tosylate monohydrate), including solid forms having desirable characteristics favorable for pharmaceutical develo ment.
- Niraparib has the following structure:
- Niraparib is an orally available, selective poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitor.
- Methods of administering niraparib to cancer patients are also described in WO2018/005818, which is hereby incorporated by reference in its entirety.
- niraparib tosylate monohydrate 2- ⁇ 4-[(3S)-piperidin-3-yl]phen 2H-indazole 7-carboxamide 4-methylbenzenesulfonate hydrate (1 : 1 : 1) and it has the following chemical structure:
- Niraparib tosylate monohydrate drug substance is a white to off-white, non- hygroscopic crystalline solid.
- Niraparib solubility is pH independent below the pKa of 9.95, with an aqueous free base solubility of 0.7 mg/mL to 1.1 mg/mL across the physiological pH range.
- Methods for preparation of niraparib include those described in WO 2014/088983;
- Niraparib prepared according to these methods can be used in the methods of preparation of the crystalline solid forms described herein.
- crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide can be prepared from solvent systems comprising water (e.g., as described in Example 1 and Example 2).
- Crystalline Form II of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide can be produced under anhydrous conditions.
- Crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide can be produced from crystalline Form I under heating conditions (e.g., as described in Example 3).
- crystalline solid forms of 4-toluenesufonate salts of 2- ⁇ 4-[(3S)-piperidin- 3-yl]phenyl ⁇ -2H-indazole-7-carboxamide are provided herein.
- Crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide is the 4-toluenesulfonate salt and is a monohydrate.
- Crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide is also referred to by interchangeable terms such as: Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide; crystalline monohydrate Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide; crystalline Form I of niraparib tosylate monohydrate; crystalline Form I; or Form I.
- Exemplary X-ray powder diffraction data for Form I is provided in Figure 1 and Figure 6.
- Figure 2 shows an exemplary scanning differential calorimetry pattern for crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide.
- Figure 3 shows an exemplary Raman spectroscopy pattern for crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Figure 4 shows an exemplary infrared spectroscopy pattern for crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide.
- Figure 5 shows an exemplary dynamic water vapor sorption pattern for crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Crystalline Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide is the 4-toluenesulfonate salt and is a non-stoichiometric hydrate.
- Crystalline Form II of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide is also referred to by interchangeable terms such as: Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide; crystalline Form II of niraparib; crystalline Form II; or Form II.
- Crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide is the 4-toluenesulfonate salt and is an anhydrous form.
- Exemplary X-ray powder diffraction data for Form III is provided in Figure 6 and Figure 7.
- Figure 2 shows an exemplary scanning differential calorimetry pattern for crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide.
- Figure 8 shows an exemplary dynamic water vapor sorption pattern for crystalline anhydrous Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide is also referred to by interchangeable terms such as: Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide; crystalline anhydrous Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide; crystalline Form III of niraparib; crystalline Form III; or Form III.
- Figure 2 shows an exemplary scanning differential calorimetry pattern for crystalline Form III of 2- ⁇ 4-[(3S)-piperidin- 3-yl]phenyl
- Solid forms of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide described herein can have beneficial properties, including favorable properties for use in methods of treatment or in methods of manufacture of pharmaceutical formulations.
- a hydrochloride salt of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide has been shown to be highly hygroscopic.
- crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide is a non-hygroscopic solid form having suitable solubility properties, as well as favorable physical and chemical stability.
- One embodiment provides a composition comprising crystalline Form I of niraparib tosylate monohydrate substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- compositions where the crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide is characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 9.5 ⁇ 0.2, 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 24.9 ⁇ 0.2, 25.6 ⁇ 0.2, 26.0 ⁇ 0.2, and 26.9 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by X-ray diffraction pattern reflections at 2 ⁇ values of 9.5 ⁇ 0.2 and 26.0 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by X- ray diffraction pattern reflections at a 2 ⁇ values of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- compositions wherein the crystalline Form I are characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by at least two X-ray diffraction pattern reflections selected from a 2 ⁇ value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- compositions wherein the crystalline Form I is characterized by at least three X-ray diffraction pattern reflections selected from a 2 ⁇ value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by at least four X-ray diffraction pattern reflections selected from a 2 ⁇ value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- composition wherein the crystalline Form I is characterized by a scanning differential calorimetry pattern substantially as shown in Figure 2.
- compositions wherein the crystalline Form I are characterized by a Raman spectroscopy pattern substantially as shown in Figure 3.
- Another embodiment provides the composition wherein the crystalline Form I is characterized by an infrared spectroscopy pattern substantially as shown in Figure 4.
- Another embodiment provides the composition wherein the crystalline Form I is characterized by a dynamic water vapor sorption pattern substantially as shown in Figure 5.
- One embodiment provides a composition comprising crystalline Form II of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4- [(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- One embodiment provides a composition comprising crystalline Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide.
- compositions comprising comprising crystalline Form II 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4- [(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- crystalline Form II is characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 9.7 ⁇ 0.3, 12.8 ⁇ 0.3, 17.9 ⁇ 0.3, 19.7 ⁇ 0.3, and 21.8 ⁇ 0.3.
- crystalline Form II has an X-ray powder diffraction pattern substantially as shown in Figure 9 for Form II.
- One embodiment provides a composition comprising crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4- [(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline Form II of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- One embodiment provides a composition comprising crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7- carboxamide.
- One embodiment provides crystalline Form III characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 17.8 ⁇ 0.2, 19.0 ⁇ 0.2, or 22.8 ⁇ 0.2.
- One embodiment provides crystalline Form III that has an X-ray powder diffraction pattern substantially as shown in Figure 9 for Form III.
- One embodiment provides crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide that has an X-ray powder diffraction pattern substantially as shown in Figure 7.
- One embodiment provides crystalline Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide characterized by a dynamic water vapor sorption pattern substantially as shown in Figure 8.
- One embodiment provides crystalline Form III of 2- ⁇ 4- [(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide characterized by a scanning differential calorimetry pattern substantially as shown in Figure 2.
- Niraparib is a selective poly(ADP-ribose) polymerase (PARP) 1 and 2 inhibitor which selectively kills tumor cells in vitro and in mouse xenograft models.
- PARP inhibition leads to irreparable double strand breaks (DSBs), use of the error-prone DNA repair pathway, resultant genomic instability, and ultimately cell death. Additionally, PARP trapped at genetic lesions as a result of the suppression of autoparlyation can contribute to cytotoxicity.
- PARP poly(ADP-ribose) polymerase
- ZEJULATM is indicated for the maintenance or treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer following a complete or partial response to platinum-based chemotherapy.
- Each ZEJULATM capsule contains 100 mg of niraparib (as tosylate monohydrate).
- the hard capsules have a white body with "100 mg” printed in black ink, and a purple cap with "Niraparib” printed in white ink.
- the recommended dose of ZEJULATM as monotherapy is three 100 mg capsules taken orally once daily, equivalent to a total daily dose of 300 mg.
- an oral composition containing niraparib or its pharmaceutically acceptable salts includes from about 20 wt% to about 60 wt% of niraparib for treatment of a disorder or condition such as cancer; and a pharmaceutically acceptable carrier, wherein the niraparib is distributed with substantial uniformity throughout the pharmaceutically acceptable carrier.
- the disorder or condition is cancer, for example, ovarian cancer.
- the niraparib is a pharmaceutically acceptable salt thereof.
- the pharmaceutically acceptable salt is niraparib tosylate monohydrate.
- the niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the pharmaceutical composition comprises about 50 mg to about 300 mg of niraparib tosylate monohydrate. In some embodiments, the pharmaceutical composition comprises about 50 mg to about 300 mg of niraparib tosylate monohydrate as a crystalline Form I substantially free of Form II and Form III. Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the pharmaceutical composition can comprise about 100 mg to about 200 mg of niraparib tosylate monohydrate.
- the pharmaceutical composition can comprise about 125 mg to about 175 mg of niraparib tosylate monohydrate.
- the formulation can comprise one or more components, including niraparib.
- the components can be combined to create a powder blend that is used to fill capsules.
- the powder blend can be filled into gelatin capsules, such as size 0 gelatin capsules.
- the niraparib may be present in the formulation as a pharmaceutically acceptable salt.
- the niraparib can be niraparib tosylate monohydrate.
- the formulation can comprise one or more diluents.
- the formulation can comprise lactose monohydrate.
- the formulation can comprise one or more lubricants.
- the formulation can comprise magnesium stearate.
- An exemplary niraparib formulation of the present invention comprises 100 mg of niraparib (based on free base, 1.000 mg niraparib anhydrous free base is equivalent to 1.594 mg niraparib tosylate monohydrate), 254.5 mg of lactose monohydrate and magnesium stearate.
- An exemplary niraparib formulation of the present invention comprises 100 mg of niraparib (based on free base, 1.000 mg niraparib anhydrous free base is equivalent to 1.594 mg niraparib tosylate monohydrate), 254.5 mg of lactose monohydrate, and magnesium stearate. It may also optionally
- formulations can be made that achieve therapeutically effective pharmacokinetic profiles.
- therapeutically effective doses of niraparib can be administered once, twice or three times daily in capsules using the manufacturing methods and compositions that have been described herein to achieve these results.
- the niraparib is present in an amount of from about 20-80 wt %, about 45-70 wt %, about 40-50 wt %, about 45-55 wt %, about 50-60 wt %, about 55-65 wt %, about 60-70 wt %, about 65-75 wt %, about 70-80 wt %, or about 40-60 wt %.
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III. Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the compositions described herein have a concentration of niraparib of from about 1% to about 50%, from about 5% to about 50%, from about 10% to about 50%, from about 15%) to about 50%>, from about 20%> to about 50%>, from about 25%> to about 50%>, from about 30%) to about 50%), from about 35%> to about 50%>, from about 40%> to about 50%>, or from about 45%o to about 50%> by weight of the composition.
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III. Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the compositions described herein have a concentration of niraparib of from about 1%> to about 45%>, from about 5%> to about 45%>, from about 10%> to about 45%>, from about 15%) to about 45%>, from about 20%> to about 45%>, from about 25%> to about 45%>, from about 30%) to about 45%o, from about 35%> to about 45%>, or from about 40%> to about 45%> by weight of the composition.
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- compositions described herein have a concentration of niraparib of from about 1% to about 40%, from about 5% to about 40%, from about 10% to about 40%, from about 15% to about 40%, from about 20% to about 40%, from about 25% to about 40%, from about 30%) to about 40%), from about 35% to about 40% by weight of the composition.
- concentration of niraparib of from about 1% to about 40%, from about 5% to about 40%, from about 10% to about 40%, from about 15% to about 40%, from about 20% to about 40%, from about 25% to about 40%, from about 30%) to about 40%, from about 35% to about 40% by weight of the composition.
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the compositions described herein have a concentration of niraparib of from about 1%> to about 35%, from about 5% to about 35%, from about 10% to about 35%, from about 15%) to about 35%, from about 20% to about 35%, from about 25% to about 35%, or from about 30%) to about 35% by weight of the composition.
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the compositions described herein have a concentration of niraparib of about 1%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, or 50% by weight of the composition. In some embodiments, the compositions described herein have a concentration of niraparib tosylate monohydrate of about 19.16%) by weight of the composition. In some embodiments, the
- compositions described herein have a concentration of niraparib tosylate monohydrate of about 38.32%) by weight of the composition. In some embodiments, the compositions described herein have a concentration of niraparib tosylate monohydrate of about 57.48%) by weight of the composition.
- compositions described herein have a concentration of niraparib tosylate monohydrate of about 76.64%) by weight of the composition. In some embodiments, the compositions described herein have a concentration of niraparib tosylate monohydrate of about 76.64%) by weight of the composition. In some embodiments, the compositions described herein have a concentration of niraparib tosylate monohydrate of about 76.64%) by weight of the composition. In some
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the compositions described herein have an amount of niraparib of from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 25 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg to 900 mg, 900 mg,
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- compositions described herein can have an amount of niraparib tosylate monohydrate of from about 1 mg to about 1000 mg, for example, from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 25 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850
- the compositions described herein have an amount of niraparib of about 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg.
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- compositions described herein can have an amount of niraparib tosylate monohydrate of about 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg.
- the compositions described herein have an amount of niraparib of about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg.
- the compositions described herein can have an amount of niraparib tosylate monohydrate of about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg.
- the compositions described herein have an amount of niraparib tosylate monohydrate of about 79.7 mg.
- compositions described herein have an amount of niraparib tosylate monohydrate of about 159.4 mg. In some embodiments, the compositions described herein have an amount of niraparib tosylate monohydrate of about 159.4 mg, wherein the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III. In some embodiments, the
- compositions described herein have an amount of niraparib tosylate monohydrate of about 159.4 mg, wherein the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- the compositions described herein have an amount of niraparib tosylate monohydrate of about 159.4 mg, wherein the niraparib tosylate monohydrate is the crystalline Form I with an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the compositions described herein have an amount of niraparib tosylate monohydrate of about 318.8 mg.
- the compositions described herein have an amount of niraparib tosylate monohydrate of about 478.2 mg.
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the pharmaceutical composition disclosed herein comprises one or more pharmaceutically acceptable excipients.
- exemplary pharmaceutically acceptable excipients for the purposes of pharmaceutical compositions disclosed herein include, but are not limited to, binders, disintegrants, superdisintegrants, lubricants, diluents, fillers, flavors, glidants, sorbents, solubilizers, chelating agents, emulsifiers, thickening agents, dispersants, stabilizers, suspending agents, adsorbents, granulating agents, preservatives, buffers, coloring agents and sweeteners or
- binders include microcrystalline cellulose, hydroxypropyl methylcellulose, carboxyvinyl polymer, polyvinylpyrrolidone, polyvinylpolypyrrolidone,
- carboxymethylcellulose calcium carboxymethylcellulose sodium, ceratonia, chitosan, cottonseed oil, dextrates, dextrin, ethylcellulose, gelatin, glucose, glyceryl behenate, galactomannan polysaccharide, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hypromellose, inulin, lactose, magnesium aluminum silicate, maltodextrin, methylcellulose, poloxamer,
- polycarbophil polydextrose, polyethylene glycol, polyethylene oxide, polymethacrylates, sodium alginate, sorbitol, starch, sucrose, sunflower oil, vegetable oil, tocofersolan, zein, or combinations thereof.
- disintegrants include hydroxypropyl methylcellulose (HPMC), low substituted hydroxypropyl cellulose (L-HPC), croscarmellose sodium, sodium starch glycolate, lactose, magnesium aluminum silicate, methylcellulose, polacrilin potassium, sodium alginate, starch, or combinations thereof.
- Examples of a lubricant include stearic acid, sodium stearyl fumarate, glyceryl behenate, calcium stearate, glycerin monostearate, glyceryl palmitostearate, magnesium lauryl sulfate, mineral oil, palmitic acid, myristic acid, poloxamer, polyethylene glycol, sodium benzoate, sodium chloride, sodium lauryl sulfate, talc, zinc stearate, potassium benzoate, magnesium stearate or combinations thereof.
- diluents include talc, ammonium alginate, calcium carbonate, calcium lactate, calcium phosphate, calcium silicate, calcium sulfate, cellulose, cellulose acetate, corn starch, dextrates, dextrin, dextrose, erythritol, ethylcellulose, fructose, fumaric acid, glyceryl palmitostearate, isomalt, kaolin, lactitol, lactose, magnesium carbonate, magnesium oxide, maltodextrin, maltose, mannitol, microcrystalline cellulose, polydextrose, polymethacrylates, simethicone, sodium alginate, sodium chloride, sorbitol, starch, sucrose, sulfobutylether ⁇ - cyclodextrin, tragacanth, trehalose, xylitol, or combinations thereof.
- the pharmaceutically acceptable excipient is hydroxypropyl methylcellulose (HPMC). In some embodiments, the pharmaceutically acceptable excipient is low substituted hydroxypropyl cellulose (L-HPC). In some embodiments, the pharmaceutically acceptable excipient is lactose. In some embodiments, the pharmaceutically acceptable excipient is lactose monohydrate. In some embodiments, the pharmaceutically acceptable excipient is magnesium stearate. In some
- the pharmaceutically acceptable excipient is lactose monohydrate and magnesium stearate.
- Various useful fillers or diluents include, but are not limited to calcium carbonate
- a filler such as lactose monohydrate is present in an amount of about 5-90% by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 5-80%) by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 5-70% by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 5-60%> by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 5-50% by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 5-40% by weight.
- a filler such as lactose monohydrate is present in an amount of about 5-30% by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 25-90%> by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 25-80%) by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 25-70%> by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 25-60%> by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 25-50%) by weight.
- a filler such as lactose monohydrate is present in an amount of about 25-40%) by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 40-90%) by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 40-80%> by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 40-70%) by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 40-60%> by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 40-50%> by weight.
- a filler such as lactose monohydrate is present in an amount of about 40% by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 50% by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 60% by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 70% by weight. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 80% by weight.
- a filler such as lactose monohydrate is present in an amount of from about 25 mg to about 1000 mg, from about 50 mg to about 1000 mg, from about 100 mg to about 1000 mg, from about 150 mg to about 1000 mg, from about 200 mg to about 1000 mg, from about 250 mg to about 1000 mg, from about 300 mg to about 1000 mg, from about 350 mg to about 1000 mg, from about 400 mg to about 1000 mg, from about 450 mg to about 1000 mg, or from about 500 mg to about 1000 mg.
- a filler such as lactose monohydrate can be present in an amount of from about 25 mg to about 1000 mg, from about 50 mg to about 1000 mg, from about 100 mg to about 1000 mg, from about 150 mg to about 1000 mg, from about 200 mg to about 1000 mg, from about 250 mg to about 1000 mg, from about 300 mg to about 1000 mg, from about 350 mg to about 1000 mg, from about 400 mg to about 1000 mg, from about 450 mg to about 1000 mg, or from about 500 mg to about 1000 mg.
- a filler such as lactose monohydrate is present in an amount of from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 300 mg to about 350 mg, from about 350 mg to about 400 mg, from about 400 mg to about 450 mg, from about 450 mg to about 500 mg, or from about 500 mg to about 550 mg.
- a filler such as lactose monohydrate can be present in an amount of from about 25 mg to about 50 mg, from about 50 mg to about 100 mg, from about 100 mg to about 150 mg, from about 150 mg to about 200 mg, from about 200 mg to about 250 mg, from about 250 mg to about 300 mg, from about 300 mg to about 350 mg, from about 350 mg to about 400 mg, from about 400 mg to about 450 mg, from about 450 mg to about 500 mg, or from about 500 mg to about 550 mg.
- a filler such as lactose monohydrate is present in an amount of about 15 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg.
- a filler such as lactose monohydrate can be present in an amount of about 15 mg, about 25 mg, about 50 mg, about 100 mg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, or about 500 mg.
- a filler such as lactose monohydrate is present in an amount of about 334.2 mg.
- a filler such as lactose monohydrate is present in an amount of about 254.5 mg.
- a filler such as lactose monohydrate is present in an amount of about 174.8 mg. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 95.1 mg. In some embodiments, a filler such as lactose monohydrate is present in an amount of about 15.4 mg.
- Various useful disintegrants include, but are not limited to, alginic acid (ProtacidTM, Satialgine H8TM), calcium phosphate, tribasic (TRI-TABTM), carboxymethylcellulose calcium (ECG 505TM), carboxymethylcellulose sodium (AkucellTM, FinnfixTM, Nymcel Tylose CBTM), colloidal silicon dioxide (AerosilTM, Cab-O-SilTM, Wacker HDKTM), croscarmellose sodium (Ac-Di-SolTM, Pharmacel XLTM, PrimelloseTM, SolutabTM, VivasolTM), crospovidone (Collison CLTM, Collison CL- MTM, Polyplasdone XLTM), docusate sodium, guar gum (MeyprodorTM, MeyprofmTM, MeyproguarTM), low substituted hydroxypropyl cellulose, magnesium aluminum silicate
- a disintegrant is optionally used in an amount of about 0-10 % by weight. In some embodiments, a disintegrant is present in an amount of from about 0.1 mg to 0.5 mg, 0.5 mg to 1 mg, 1 mg to 2 mg, 2 mg to 2.5 mg, 2.5 mg to 5 mg, 5 mg to 7.5 mg, 7 mg to 9.5 mg, 9 mg to 11.5 mg, 11 mg to 13.5 mg, 13 mg to 15.5 mg, 15 mg to 17.5 mg, 17 to 19.5 mg, 19 mg to 21.5 mg, 21 mg to 23.5 mg, 23 mg to 25.5 mg, 25 mg to 27.5 mg, 27 mg to 30 mg, 29 mg to 31.5 mg, 31 mg to 33.5 mg, 33 mg to 35.5 mg, 35 mg to 37.5 mg, 37 mg to 40 mg, 40 mg to 45 mg, 45 mg to 50 mg, 50 mg to 55 mg, 55 mg to 60 mg, 60 mg to 65 mg, 65 mg to 70 mg, 70 mg to 75 mg, 75 mg to 80 mg, 80 mg to 85 mg, 85 mg to 90 mg, 90
- a disintegrant is present in an amount of about 0.1 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 5 mg, 7 mg, 9 mg, 11 mg, 13 mg, 15 mg, 17 mg, 19 mg, 21 mg, 23 mg, 25 mg, 27.5 mg, 30 mg, 31.5 mg, 33.5 mg, 35.5 mg, 37.5 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg.
- Various useful lubricants include, but are not limited to, calcium stearate (HyQualTM), glycerine monostearate (ImwitorTM 191 and 900, Kessco GMS5TM, 450 and 600, Myvaplex 600PTM, MyvatexTM, Rita GMSTM, Stepan GMSTM, TeginTM, TeginTM 503 and 515, Tegin 4100TM, Tegin MTM, Unimate GMSTM), glyceryl behenate (Compritol 888 ATOTM), glyceryl palmitostearate (Precirol ATO 5TM), hydrogenated castor oil (Castorwax MP 80TM, CroduretTM, Cutina HRTM, FancolTM, Simulsol 1293TM), hydrogenated vegetable oil 0 type I (SterotexTM, Dynasan P60TM, HydrocoteTM, Lipovol HS-KTM, Sterotex HMTM), magnesium lauryl sulphate, magnesium stea
- Suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, zinc stearate, stearic acid, talc, glyceryl behenate, polyethylene glycol, polyethylene oxide polymers, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, DL-leucine, colloidal silica, and others as known in the art.
- a lubricant is magnesium stearate.
- a lubricant such as magnesium stearate is present in an amount of about 0.1-5% by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.1-2% by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.1-1% by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.1-0.75%) by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.1-5% by weight.
- a lubricant such as magnesium stearate is present in an amount of about 0.2-5% by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.2-2%) by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.2-l%> by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.2-0.75%) by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.3%> by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.4% by weight.
- a lubricant such as magnesium stearate is present in an amount of about 0.5% by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.6%) by weight. In some embodiments, a lubricant such as magnesium stearate is present in an amount of about 0.7% by weight.
- a lubricant is present in an amount of from about 0.01 mg to 0.05 mg, 0.05 mg to 0.1 mg, 0.1 mg to 0.2 mg, 0.2 mg to 0.25 mg, 0.25 mg to 0.5 mg, 0.5 mg to 0.75 mg, 0.7 mg to 0.95 mg, 0.9 mg to 1.15 mg, 1.1 mg to 1.35 mg, 1.3 mg to 1.5 mg, 1.5 mg to 1.75 mg, 1.75 to 1.95 mg, 1.9 mg to 2.15 mg, 2.1 mg to 2.35 mg, 2.3 mg to 2.55 mg, 2.5 mg to 2.75 mg, 2.7 mg to 3.0 mg, 2.9 mg to 3.15 mg, 3.1 mg to 3.35 mg, 3.3 mg to 3.5 mg, 3.5 mg to 3.75 mg, 3.7 mg to 4.0 mg, 4.0 mg to 4.5 mg, 4.5 mg to 5.0 mg, 5.0 mg to 5.5 mg, 5.5 mg to 6.0 mg, 6.0 mg to 6.5 mg, 6.5 mg to 7.0 mg, 7.0 mg to 7.5 mg, 7.5 mg to 8.0 mg,
- a lubricant is present in an amount of about 0.01 mg, 0.05 mg, 0.1 mg, 0.2 mg, 0.25 mg, 0.5 mg, 0.7 mg, 0.9 mg, 1.1 mg, 1.3 mg, 1.5 mg, 1.7 mg, 1.9 mg, 2. mg, 2.3 mg, 2.5 mg, 2.75 mg, 3.0 mg, 3.1 mg, 3.3 mg, 3.5 mg, 3.7 mg, 4.0 mg, 4.5 mg, 5.0 mg, 5.5 mg, 6.0 mg, 6.5 mg, 7.0 mg, 7.5 mg, 8.0 mg, 8.5 mg, 9.0 mg, 9.5 mg, or 10.0 mg.
- Various useful glidants include, but are not limited to, tribasic calcium phosphate (TRI- TABTM), calcium silicate, cellulose, powdered (SanacelTM, Solka- FloeTM), colloidal silicon dioxide (AerosilTM, Cab-O-Sil M-5PTM, Wacker HDKTM), magnesium silicate, magnesium trisilicate, starch (MelojelTM, MeritenaTM, Paygel 55TM, Perfectamyl D6PHTM, Pure-BindTM, Pure-CoteTM, Pure- DentTM, Pure-GelTM, Pure-SetTM, Purity 21TM, Purity 826TM, Tablet WhiteTM) and talc (Luzenac PharmaTM, Magsil OsmanthusTM, Magsil StarTM, SuperioreTM), or mixtures thereof.
- a glidant is optionally used in an amount of about 0-15% by weight. In some embodiments, a glidant is present in an amount of from about 0.1 mg to 0.5 mg, 0.5 mg to 1 mg, 1 mg to 2 mg, 2 mg to 2.5 mg, 2.5 mg to 5 mg, 5 mg to 7.5 mg, 7 mg to 9.5 mg, 9 mg to 11.5 mg, 11 mg to 13.5 mg, 13 mg to 15.5 mg, 15 mg to 17.5 mg, 17 to 19.5 mg, 19 mg to 21.5 mg, 21 mg to 23.5 mg, 23 mg to 25.5 mg, 25 mg to 27.5 mg, 27 mg to 30 mg, 29 mg to 31.5 mg, 31 mg to 33.5 mg, 33 mg to 35.5 mg, 35 mg to 37.5 mg, 37 mg to 40 mg, 40 mg to 45 mg, 45 mg to 50 mg, 50 mg to 55 mg, 55 mg to 60 mg, 60 mg to 65 mg, 65 mg to 70 mg, 70 mg to 75 mg, 75 mg to 80 mg, 80 mg to 85 mg, 85 mg to 90 mg,
- a glidant is present in an amount of about 0.1 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 5 mg, 7 mg, 9 mg, 11 mg, 13 mg, 15 mg, 17 mg, 19 mg, 21 mg, 23 mg, 25 mg, 27.5 mg, 30 mg, 31.5 mg, 33.5 mg, 35.5 mg, 37.5 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or 100 mg.
- Pharmaceutically acceptable surfactants include, but are limited to both non-ionic and ionic surfactants suitable for use in pharmaceutical dosage forms.
- Ionic surfactants may include one or more of anionic, cationic or zwitterionic surfactants.
- Various useful surfactants include, but are not limited to, sodium lauryl sulfate, monooleate, monolaurate, monopalmitate, monostearate or another ester of olyoxyethylene sorbitane, sodium dioctylsulfosuccinate (DOSS), lecithin, stearyic alcohol, cetostearylic alcohol, cholesterol, polyoxyethylene ricin oil, polyoxyethylene fatty acid glycerides, poloxamer, or any other commercially available co-processed surfactant like SEPITRAP ® 80 or SEPITRAP ® 4000 and mixtures thereof.
- surfactant is optionally used in an amount of about 0-5% by weight.
- a surfactant is present in an amount of from about 0.1 mg to 0.5 mg, 0.5 mg to 1 mg, 1 mg to 2 mg, 2 mg to 2.5 mg, 2.5 mg to 5 mg, 5 mg to 7.5 mg, 7 mg to 9.5 mg, 9 mg to 11.5 mg, 11 mg to 13.5 mg, 13 mg to 15.5 mg, 15 mg to 17.5 mg, 17 to 19.5 mg, 19 mg to 21.5 mg, 21 mg to 23.5 mg, 23 mg to 25.5 mg, 25 mg to 27.5 mg, 27 mg to 30 mg, 29 mg to 31.5 mg, 31 mg to 33.5 mg, 33 mg to 35.5 mg, 35 mg to 37.5 mg, 37 mg to 40 mg, 40 mg to 45 mg, 45 mg to 50 mg, 50 mg to 55 mg, 55 mg to 60 mg, 60 mg to 65 mg, 65 mg to 70 mg, 70 mg to 75 mg, 75 mg to 80 mg, 80 mg to 85 mg, 85 mg to 90 mg, 90 mg to 95 mg
- a surfactant is present in an amount of about 0.1 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 5 mg, 7 mg, 9 mg, 11 mg, 13 mg, 15 mg, 17 mg, 19 mg, 21 mg, 23 mg, 25 mg, 27.5 mg, 30 mg, 31.5 mg, 33.5 mg, 35.5 mg, 37.5 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg,
- the pharmaceutical composition disclosed herein is stable for at least about: 30 days, 60 days, 90 days, 6 months, 1 year, 18 months, 2 years, 3 years, 4 years, or 5 years, for example about 80%- 100% such as about: 80%, 90%, 95%, or 100% of the active pharmaceutical agent in the pharmaceutical composition is stable, e.g., as measured by High Performance Liquid Chromatography (HPLC).
- HPLC High Performance Liquid Chromatography
- about 80%-100% e.g., about: 90%-100% or 95- 100%
- niraparib or a pharmaceutically acceptable salt thereof e.g., niraparib tosylate
- monohydrate in the pharmaceutical composition disclosed herein is stable for at least about: 30, 60, 90, 180, 360, 540, or 720 days, for example greater than 90 days, which can be measured by HPLC.
- about: 80%, 85%, 90%, 95%, or 100% (e.g., about 95%) of the crystalline Form I of niraparib tosylate monohydrate is stable for 30 days or more.
- the pharmaceutical formulations described herein are stable with respect to compound degradation (e.g., less than 30% degradation, less than 25% degradation, less than 20%) degradation, less than 15% degradation, less than 10% degradation, less than 8%
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least about 1 week.
- the formulations described herein are stable with respect to compound degradation over a period of at least
- formulations described herein are stable with respect to compound degradation over a period of at least about 1 month. In some embodiments, the formulations described herein are stable with respect to compound degradation over a period of at least about 3 months. In some embodiments, the formulations described herein are stable with respect to compound degradation over a period of at least about 6 months. In some embodiments, the formulations described herein are stable with respect to compound degradation over a period of at least about 9 months. In some embodiments, the formulations described herein are stable with respect to compound degradation over a period of at least about 12 months. [0087] Methods for assessing the chemical storage stability of solid dosage forms under accelerated aging conditions have been described in the literature. See, e.g., S. T. Colgan, T. J. Watson, R.
- the pharmaceutical composition is formulated into solid oral pharmaceutical dosage forms.
- Solid oral pharmaceutical dosage forms include, but are not limited to, tablets, capsules, powders, granules and sachets.
- the solid oral pharmaceutical dosage form can be a capsule.
- a therapeutically effective amount of niraparib administered to a subject via a solid dosage form is in the range of about 1 mg to about 1000 mg.
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- niraparib administered to a subject via a solid dosage form is in the range of from about 50 mg to about 300 mg.
- a therapeutically effective amount of niraparib administered to a subject via a solid dosage form is in the range of from about 50 mg to about 300 mg, wherein the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the dosage form comprising niraparib as the crystalline Form I of niraparib tosylate monohydrate with an X-ray powder diffraction pattern substantially as shown in Figure 1.
- a niraparib formulation is administered as a solid dosage form at a concentration of about 50 mg to about 100 mg.
- the niraparib formulation is administered as a solid dosage form at concentration of about 100 mg to about 300 mg.
- a therapeutically effective amount of niraparib tosylate monohydrate crystalline Form I substantially free of Form II and Form III thereof administered to a subject via a solid dosage form can be from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg
- a therapeutically effective amount of niraparib tosylate monohydrate administered to a subject via a solid dosage form can be from about 1 mg to about 1000 mg, for example, from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to
- a therapeutically effective amount of niraparib administered to a subject via a solid dosage form can be from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 25 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg to
- a therapeutically effective amount of niraparib tosylate monohydrate administered to a subject via a solid dosage form can be from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 25 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the solid oral dosage form can be administered one, two, or three times a day (b.i.d).
- a therapeutically effective amount of niraparib administered to a subject via a solid dosage form can be about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 25 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg to
- a therapeutically effective amount of niraparib tosylate monohydrate administered to a subject via a solid dosage form can be about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg,
- the niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the composition wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- a therapeutically effective amount of niraparib tosylate monohydrate administered to a subject via a solid dosage form is about 79.7 mg.
- a therapeutically effective amount of niraparib tosylate monohydrate administered to a subject via a solid dosage form is about 159.4 mg. In some embodiments, a therapeutically effective amount of niraparib tosylate monohydrate administered to a subject via a solid dosage form is about 159.4 mg, wherein the niraparib is niraparib tosylate monohydrate is a crystalline Form I
- a therapeutically effective amount of niraparib tosylate monohydrate administered to a subject via a solid dosage form is about 318.8 mg. In some embodiments, a therapeutically effective amount of niraparib tosylate monohydrate administered to a subject via a solid dosage form is about 478.2 mg. In some aspects, the solid oral dosage form can be administered one, two, or three times a day (b.i.d).
- compositions of the present invention provide a therapeutically effective amount of niraparib over an interval of about 30 minutes to about 8 hours after administration, enabling, for example, once-a-day, twice-a-day, three times a day, and etc. administration if desired.
- the weight ratio of an active pharmaceutical ingredient e.g., niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III
- a non-active pharmaceutical ingredient e.g., lactose monohydrate
- the weight ratio of an active pharmaceutical ingredient is from about 1:10 to about 10:1, respectively, for example about 1:2, about 1:3, about 1:4, about 1:5, about 1:6, about 1:7, about 1:8, about 1:9, about 1:10, about 10:1, about 9:1, about 8:1, about 7:1, about 6:1, about 5:1, about 4:1, about 3:1, or about 2:1.
- the weight ratio of an active pharmaceutical ingredient e.g., niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III
- a non-active pharmaceutical ingredient e.g., magnesium stearate
- the weight ratio of a non-active pharmaceutical ingredient (e.g., lactose monohydrate or magnesium stearate) to an active pharmaceutical ingredient (e.g., niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III) to is from about 3 :2 to about 11:1, from about 3 : 1 to about 7:1, from about 1:1 to about 5:1, from about 9:2 to about 11:2, from about 4:2 to about 6:2, about 5:1, or about 2.5:1.
- the weight ratio of an active pharmaceutical ingredient e.g., niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III
- a non- active pharmaceutical ingredient e.g., lactose monohydrate or magnesium stearate
- the weight ratio of an active pharmaceutical ingredient e.g., niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III
- a non-active pharmaceutical ingredient e.g., lactose monohydrate or magnesium stearate
- the weight ratio of niraparib tosylate monohydrate to lactose monohydrate is about 38:61, for example, 38.32:61.18. In some embodiments, the weight ratio of niraparib tosylate monohydrate to magnesium stearate is about 77:1, for example, 76.64:1.
- the weight ratio of a first non-active pharmaceutical ingredient to a second non-active pharmaceutical ingredient is from about 5:1 to about 200:1, respectively, for example about 5:1, about 10:1, about 20:1, about 40:1, about 50:1, about 75:1, about 100:1, about 110:1, about 120:1, about 130:1, about 140:1, about 150:1, about 160:1, about 170:1, about 180:1, about 190:1, or about 200:1.
- the weight ratio of lactose monohydrate to magnesium stearate is about 120:1 to about 125:1. In some embodiments, the weight ratio of lactose monohydrate to magnesium stearate is about 122.36:1.
- Any subject having cancer including breast cancer, ovarian cancer, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, prostate cancer, testicular cancer, pancreatic cancer, esophageal cancer, head and neck cancer, gastric cancer, bladder cancer, lung cancer (e.g., adenocarcinoma, NSCLC and SCLC), bone cancer (e.g., osteosarcoma), colon cancer, rectal cancer, thyroid cancer, brain and central nervous system cancers, glioblastoma, neuroblastoma, neuroendocrine cancer, rhabdoid cancer, keratoacanthoma, epidermoid carcinoma, seminoma, melanoma, sarcoma (e.g., liposarcoma), bladder cancer, liver cancer (e.g., hepatocellular carcinoma), kidney cancer (e.g., renal cell carcinoma), myeloid disorders (e.g., AML, CML,
- the methods of the invention treat subjects with ovarian cancer. In some embodiments, the methods of the invention treat subjects with epithelial ovarian cancer. In some embodiments, the methods of the invention treat subjects with fallopian tube cancer. In some embodiments, the methods of the invention treat subjects with primary peritoneal cancer.
- the methods of the invention treat subjects with recurrent ovarian cancer. In some embodiments, the methods of the invention treat subjects with recurrent epithelial ovarian cancer. In some embodiments, the methods of the invention treat subjects with recurrent fallopian tube cancer. In some embodiments, the methods of the invention treat subjects with recurrent primary peritoneal cancer.
- the methods of the invention treat subjects with recurrent ovarian cancer following a complete or partial response to a chemotherapy, such as a platinum-based chemotherapy.
- the methods of the invention treat subjects with recurrent epithelial ovarian cancer following a complete or partial response to a chemotherapy, such as a platinum-based chemotherapy.
- the methods of the invention treat subjects with recurrent fallopian tube cancer following a complete or partial response to a chemotherapy, such as a platinum-based chemotherapy.
- the methods of the invention treat subjects with recurrent primary peritoneal cancer following a complete or partial response to a chemotherapy, such as a platinum-based chemotherapy.
- the methods of the invention treat subjects with recurrent ovarian cancer, recurrent epithelial ovarian cancer, recurrent fallopian tube cancer and/or recurrent primary peritoneal cancer following a complete or partial response to a platinum-based chemotherapy, wherein the subjects begin the treatment no later than 8 weeks after their most recent platinum- containing regimen.
- subjects can begin treatment with niraparib about 7 weeks after their most recent platinum-containing regimen.
- subjects can begin treatment with niraparib about 6 weeks after their most recent platinum-containing regimen.
- subjects can begin treatment with niraparib about 6 weeks after their most recent platinum-containing regimen.
- subjects can begin treatment with niraparib about 5 weeks after their most recent platinum-containing regimen.
- subjects can begin treatment with niraparib about 4 weeks after their most recent platinum-containing regimen.
- subjects can begin treatment with niraparib about 3 weeks after their most recent platinum-containing regimen.
- subjects can begin treatment with niraparib about 2 weeks after their most recent platinum- containing regimen.
- subjects can begin treatment with niraparib about 1 week after their most recent platinum-containing regimen.
- the methods of the invention treat subjects with prostate cancer
- the methods of the invention treat subjects with a pediatric cancer.
- exemplary pediatric cancers include, but are not limited to adrenocortical carcinoma, astrocytoma, atypical teratoid rhabdoid tumor, brain tumors, chondroblastoma, choroid plexus tumor,
- craniopharyngioma desmoid tumor, dysembryplastic neuroepithelial tumor (DNT), ependymoma, fibrosarcoma, germ cell tumor of the brain, glioblastoma multiforme, diffuse pontine glioma, low grade glioma, gliomatosis cerebri, hepatoblastoma, histiocytosis, kidney tumor, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myelogenous leukemia (CML),
- ALL acute lymphoblastic leukemia
- AML acute myeloid leukemia
- CML chronic myelogenous leukemia
- liposarcoma liver cancer, Burkitt lymphoma, Hodgkin lymphoma, non-Hodgkin lymphoma, malignant fibrous histiocytoma, melanoma, myelodysplastic syndrome, nephroblastoma,
- neuroblastoma neurofibrosarcoma, osteosarcoma, pilocytic astrocytoma, retinoblastoma, rhabdoid tumor of the kidney, rhabdomyosarcoma, Ewing sarcoma, soft tissue sarcoma, synovial sarcoma, spinal cord tumor and Wilm's tumor.
- the methods of the invention treat subjects with a cancer with a dosage of 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg of niraparib once-daily, twice-daily, or thrice-daily.
- the methods of the invention treat subjects with a cancer with a dosage of 150 mg to 175 mg, 170 mg to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 to 295 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, or 370 mg to 400 mg of niraparib once-daily, twice-daily, or thrice-daily.
- the methods of the invention treat subjects with a cancer with a dosage of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg.
- the methods of the invention treat subjects with a cancer with a dosage of from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg to 900 mg, 900 mg to
- the methods of the invention treat subjects with a cancer with a dosage of from about 5 mg to 7.5 mg, 7 mg to 9.5 mg, 9 mg to 11.5 mg, 11 mg to 13.5 mg, 13 mg to 15.5 mg, 15 mg to 17.5 mg, 17 to 19.5 mg, 19 mg to 21.5 mg, 21 mg to 23/5 mg, 23 mg to 25.5 mg, 25 mg to 27.5 mg, 27 mg to 30 mg, 30 mg to 35 mg, 35 mg to 40 mg, 40 mg to 45 mg, 45 mg to 50 mg, 50 mg to 55 mg, 55 mg to 60 mg, 60 to 65 mg, 65 mg to 70 mg, 70 mg to 75 mg, 75 mg to 80 mg, 80 mg to 85 mg, 85 mg to 90 mg, 90 mg to 95 mg, or 95 mg to 100 mg of niraparib once-daily, twice-daily, or thrice-daily.
- the recommended dose of the niraparib capsule formulations described herein as monotherapy is three 100 mg capsules taken orally once daily, equivalent to a total daily dose of 300 mg. Patients may be encouraged to take their dose at approximately the same time each day. Bedtime administration may be a potential method for managing nausea.
- doses of 1 to 1000 mg of niraparib may be administered for treatment of subjects, and methods and compositions described herein may comprise once-daily, twice-daily, or thrice-daily administration of a dose of up to 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg once-daily, twice-daily, or thrice-daily.
- the dose of niraparib is from 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg to 900 mg, 900 mg to 950 mg, or 950 mg to 1000 mg,
- the methods of the invention treat subjects with a cancer with a dosage of 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg of niraparib once-daily, twice-daily, or thrice-daily.
- a total daily dose of niraparib of 1 mg to 1000 mg, for example, or 50 to 300 mg is administered.
- the daily dose of niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the daily dosage wherein the crystalline Form I of niraparib tosylate monohydrate has an X- ray powder diffraction pattern substantially as shown in Figure 1.
- the total daily dose of niraparib administered exceeds 100 mg per day. In some embodiments, the total daily dose of niraparib administered exceeds 200 mg per day.
- the total daily dose of niraparib administered exceeds 300 mg per day. In some embodiments, the total daily dose of niraparib administered exceeds 400 mg per day. In some embodiments, the total daily dose of niraparib administered exceeds 500 mg per day.
- the total daily dose of niraparib administered does not exceed 500 mg per day.
- the daily dose of niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the daily dosage wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- the total daily dose of niraparib administered does not exceed 300 mg per day.
- the total daily dose of niraparib administered does not exceed 100 mg per day.
- the total daily dose of niraparib administered does not exceed 50 mg per day.
- the total daily dose of niraparib is from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg to 900 mg, 900 mg to 950 mg, or 950 mg,
- the total daily dose of niraparib is about 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg.
- the daily dose of niraparib is niraparib tosylate monohydrate is a crystalline Form I substantially free of Form II and Form III.
- Another embodiment provides the daily dosage wherein the crystalline Form I of niraparib tosylate monohydrate has an X-ray powder diffraction pattern substantially as shown in Figure 1.
- a therapeutically effective dose of niraparib tosylate monohydrate as a crystalline Form I substantially free of Form II and Form III is about 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg per day.
- the amount of niraparib administered daily is from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg to 900 mg, 900 mg to 950 mg, or 950 mg,
- the amount of niraparib tosylate monohydrate as a crystalline Form I substantially free of Form II and Form III is administered one time daily is 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800
- the amount of naraparib administered one time daily is 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg.
- the amount of niraparib tosylate monohydrate as a crystalline Form I substantially free of Form II and Form III is administered two times daily is 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800
- the amount of niraparib administered two times daily is 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg.
- the amount of niraparib tosylate monohydrate as a crystalline Form I substantially free of Form II and Form III is administered three times daily is 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, l lO mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to 375 mg, 370 mg to 400 mg, 400 mg to 450 mg, 450 mg to 500 mg, 500 mg to 550 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to
- the amount of niraparib administered three times daily is 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg.
- the niraparib tosylate monohydrate as a crystalline Form I
- substantially free of Form II and Form III is present at a dose from about 1 mg to about 1000 mg, including, but not limited to, about 1 mg, 5 mg, 10.0 mg, 10.5 mg, 11.0 mg, 11.5 mg, 12.0 mg, 12.5 mg, 13.0 mg, 13.5mg, 14.0 mg, 14.5 mg, 15.0 mg, 15.5 mg, 16 mg, 16.5 mg, 17 mg, 17.5 mg, 18 mg, 18.5 mg, 19 mg, 19.5 mg, 20 mg, 20.5 mg, 21 mg, 21.5 mg, 22 mg, 22.5 mg, 23 mg, 23.5 mg, 24 mg, 24.5 mg, 25 mg, 25.5 mg, 26 mg, 26.5 mg, 27 mg, 27.5 mg, 28 mg, 28.5 mg, 29 mg, 29.5 mg, 30 mg, 30.5 mg, 31 mg, 31.5 mg, 32 mg, 32.5 mg, 33 mg, 33.5 mg, 34 mg, 34.5 mg, 35 mg, 35.5 mg, 36 mg, 36.5 mg, 37 mg, 37.5 mg, 38 mg, 38.5 mg, 39 mg, 39.5 mg,
- the niraparib tosylate monohydrate as a crystalline Form I
- substantially free of Form II and Form III is present at a dose from about 1 mg to 5 mg, 5 mg to 10 mg, 10 mg to 20 mg, 20 mg to 25 mg, 25 mg to 100 mg, 35 mg to 140 mg, 70 mg to 140 mg, 80 mg to 135 mg, 10 mg to 25 mg, 25 mg to 50 mg, 50 mg to 100 mg, 100 mg to 150 mg, 150 mg to 200 mg, 10 mg to 35 mg, 35 mg to 70 mg, 70 mg to 105 mg, 105 mg to 140 mg, 140 mg to 175 mg, or 175 mg to 200 mg, 35 mg to 50 mg, 50 mg to 75 mg, 70 mg to 95 mg, 90 mg to 115 mg, 110 mg to 135 mg, 130 mg to 155 mg, 150 mg to 175 mg, 170 to 195 mg, 190 mg to 215 mg, 210 mg to 235 mg, 230 mg to 255 mg, 250 mg to 275 mg, 270 mg to 300 mg, 290 mg to 315 mg, 310 mg to 335 mg, 330 mg to 355 mg, 350 mg to
- a composition disclosed herein is administered to an individual in need thereof once. In some embodiments, a composition disclosed herein is administered to an individual in need thereof more than once. In some embodiments, a first administration of a composition disclosed herein is followed by a second administration of a composition disclosed herein. In some embodiments, a first administration of a composition disclosed herein is followed by a second and third administration of a composition disclosed herein. In some embodiments, a first administration of a composition disclosed herein is followed by a second, third, and fourth
- a first administration of a composition disclosed herein is followed by a second, third, fourth, and fifth administration of a composition disclosed herein. In some embodiments, a first administration of a composition disclosed herein is followed by a drug holiday.
- compositions disclosed herein are administered once to an individual in need thereof with a mild acute condition.
- a composition disclosed herein is administered more than once to an individual in need thereof with a moderate or severe acute condition.
- the administration of niraparib may be administered chronically, that is, for an extended period of time, including throughout the duration of the patient's life in order to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.
- the niraparib composition is administered at predetermined time intervals over an extended period of time. In some embodiments, the niraparib composition is administered once every day. In some embodiments, the niraparib composition is administered every other day. In some embodiments, the niraparib composition is administered over 1 week, 2 weeks, 1 month, 2 months, 3 months, 6 moths, 1 year, 2 years, 3 years, 4 years, 5 years, 6 years, 7 years, 8 years, 9 years, 10 years, 11 years, or 12-15 years.
- the niraparib composition is administered in doses having a dose-to- dose niraparib concentration variation of less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, or less than 5%.
- the administration of the niraparib may be given continuously; alternatively, the dose of drug being administered may be temporarily reduced or temporarily suspended for a certain length of time (i.e., a "drug holiday").
- the length of the drug holiday can vary between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, and 365 days.
- a first or second dose reduction during a drug holiday may be from 10%- 100%, including by way of example only 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, and 100%.
- a first or second dose reduction during a drug holiday may be a dose reduced from 5 mg to 1 mg, 10 mg to 5 mg, 20 mg to 10 mg, 25 mg to 10 mg, 50 mg to 25 mg, 75 mg to 50 mg, 75 mg to 25 mg, 100 mg to 50 mg, 150 mg to 75 mg, 100 mg to 25 mg, 200 mg to 100 mg, 200 to 50 mg, 250 mg to 100 mg, 300 mg to 50 mg, 300 mg to 100 mg, 300 mg to 200 mg, 400 mg to 50 mg, 400 mg to 100 mg, 400 mg to 200 mg, 500 mg to 50 mg, 500 mg to 100 mg, 500 mg to 250 mg, 1000 mg to 50 mg, 1000 mg to 100 mg, or 1000 mg to 500 mg, 550 mg to 600 mg, 600 mg to 650 mg, 650 mg to 700 mg, 700 mg to 750 mg, 750 mg to 800 mg, 800 mg to 850 mg, 850 mg to 900 mg, 900 mg to 950 mg, or 950 mg to 1000 mg.
- a first or second dose reduction during a drug holiday may be a dose reduced by 1 mg, 5 mg, 10 mg, 20 mg, 25 mg, 35 mg, 50 mg,75 mg, 100 mg, 125 mg, 150 mg, 175 mg, 200 mg, 225 mg, 250 mg to 275 mg, 300 mg, 325 mg, 350 mg 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, 750 mg, 800 mg, 850 mg, 900 mg, 950 mg, or 1000 mg.
- a maintenance niraparib dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is optionally reduced, as a function of the symptoms, to a level at which the improved disease, disorder or condition is retained. In certain embodiments, patients require intermittent treatment on a long- term basis upon any recurrence of symptoms.
- the Rigaku Smart-Lab X-ray diffraction system was configured for reflection Bragg- Brentano geometry using a line source X-ray beam.
- the x-ray source is a Cu Long Fine Focus tube that was operated at 40 kV and 44 ma. That source provides an incident beam profile at the sample that changes from a narrow line at high angles to a broad rectangle at low angles. Beam conditioning slits are used on the line X-ray source to ensure that the maximum beam size is less than 10mm both along the line and normal to the line.
- the Bragg-Brentano geometry is a para-focusing geometry controlled by passive divergence and receiving slits with the sample itself acting as the focusing component for the optics.
- the inherent resolution of Bragg-Brentano geometry is governed in part by the diffractometer radius and the width of the receiving slit used. Typically, the Rigaku Smart-Lab is operated to give peak widths of 0.1° 2 ⁇ or less.
- the axial divergence of the X-ray beam is controlled by 5.0-degree Soller slits in both the incident and diffracted beam paths.
- Powder samples were prepared in a low background Si holder using light manual pressure to keep the sample surfaces flat and level with the reference surface of the sample holder. Each sample was analyzed from 2 to 40 °2 ⁇ using a continuous scan of 6 °2 ⁇ per minute with an effective step size of 0.02 °2 ⁇ . Unless otherwise noted, XPRD studies were performed at room temperature and room humidity.
- DSC analyses were carried out using a TA Instruments Q2000 instrument.
- the instrument temperature calibration was performed using indium.
- the DSC cell was kept under a nitrogen purge of -50 mL per minute during each analysis.
- the sample was placed in a standard, crimped, aluminum pan and was heated from 25 °C to 350 °C at a rate of 10 °C per minute.
- Fig. 6 provides an overlay comparison of the x-ray powder diffraction patterns for Form I and Form III.
- Fig. 9 provides an overlay comparison of the x-ray powder diffraction patterns for Form I, Form II and Form III.
- Niraparib 4-toluenesulfonate monohydrate (3.01 g) was suspended in 110 mL of toluene, and the resulting mixture was heated to reflux for 2 hours, collecting toluene/water into a Dean-Stark trap. A small amount of water was observed in the trap. The slurry was allowed to cool to ambient temperature, vacuum filtered, and the solids air dried.
- Figures 1 and 6 provide the X-ray powder diffraction pattern for crystalline Form I monohydrate of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Table 2 provides a listing of the reflections.
- Figure 2 shows an exemplary scanning differential calorimetry pattern for crystalline monohydrate Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- the DSC curve of the monohydrate exhibits an endotherm at approximately 154 °C which is likely due to dehydration followed by an endotherm at approximately 231 °C which is likely due to melting.
- Figure 5 shows an exemplary dynamic water vapor sorption pattern for crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- the DVS curve of the monohydrate indicates the monohydrate is not hygroscopic. After the experiment the samples were analyzed by XRPD. The monohydrate remained unchanged.
- Figures 6 and 7 provide the X-ray powder diffraction pattern for crystalline anhydrous Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- Table 3 provides a listing of the reflections.
- Figure 2 shows an exemplary scanning differential calorimetry pattern for crystalline anhydrous Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- the DSC curve of the anhydrate exhibits an endotherm at approximately 230 °C which is likely due to melting.
- Figure 8 shows an exemplary dynamic water vapor sorption pattern for crystalline anhydrous Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- the DVS curve of the anhydrate is very hygroscopic and showed a weight gain of approximately 15.8% up to 95% RH. After the experiment the samples were analyzed by XRPD. The anhydrate converted to the monohydrate.
- a composition comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- composition of paragraph [00136] or [00137], wherein the crystalline Form I is further characterized by at least three X-ray diffraction pattern reflections selected from a 2 ⁇ value of 12.4 ⁇ 0.2, 13.2 ⁇ 0.2, 17.4 ⁇ 0.2, 18.4 ⁇ 0.2, 21.0 ⁇ 0.2, 25.6 ⁇ 0.2, and 26.9 ⁇ 0.2.
- a composition comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide, wherein the crystalline Form I is characterized by a scanning differential calorimetry pattern substantially as shown in Figure 2.
- composition of paragraph [00143] wherein the composition is the composition of any one of paragraphs [00133]-[00142].
- a composition comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide, wherein the crystalline Form I is characterized by a Raman spectroscopy pattern substantially as shown in Figure 3.
- composition of paragraph [00145] wherein the composition is the composition of any one of paragraphs [00133]-[00144].
- a composition comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide, wherein the crystalline Form I is characterized by a dynamic water vapor sorption pattern substantially as shown in Figure 5.
- composition of paragraph [00147], wherein the composition is the composition of any one of paragraphs [00133]-[00146].
- a composition comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide, wherein the crystalline Form I is characterized by an infrared spectroscopy pattern substantially as shown in Figure 4.
- composition of paragraph [00149] wherein the composition is the composition of any one of paragraphs [00133]-[00148].
- composition of any one of paragraphs [00133]-[00150], wherein the presence of Form III is characterized by at least one X-ray diffraction pattern reflection selected from a 2 ⁇ value of 17.8 ⁇ 0.2, 19.0 ⁇ 0.2, or 22.8 ⁇ 0.2.
- composition of any one of paragraphs [00133]-[00151], wherein substantially free of Form II and Form III means less than about 20% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- composition of any one of paragraphs [00133]-[00151], wherein substantially free of Form II and Form III means less than about 15% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- composition of any one of paragraphs [00133]-[00151], wherein substantially free of Form II and Form III means less than about 8% (w/w) combined total weight for Form II and Form III compared to the combined total weight of Form I, Form II and Form III.
- Form II and Form III means less than about 1% (w/w) combined total weight for Form II and Form
- a composition comprising crystalline Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline Form III of 2- ⁇ 4-[(3 S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- a composition comprising crystalline Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- a composition comprising crystalline Form II 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide and crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole- 7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide.
- a composition comprising crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide and crystalline Form II of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- a composition comprising crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide.
- composition of any one of paragraphs [00163]-[00167], wherein the crystalline Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide has an X-ray powder diffraction pattern substantially as shown in Figure 7.
- a composition comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H- indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide as described in any one of paragraphs 1-[00160], prepared by dissolving a composition comprising Form II of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole- 7-carboxamide or Form III of 2- ⁇ 4-[(3S)-piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide, or a mixture thereof, in a solvent having a water: organic solvent ratio of about 10: 1 to about 400: 1 (v/v), and crystallizing the crystalline Form I.
- composition of any one of paragraphs [00133]-[00172] and [00180]-[00186], wherein the composition is a pharmaceutical composition.
- a pharmaceutical composition comprising crystalline Form I of 2- ⁇ 4-[(3S)-piperidin-3- yl]phenyl ⁇ -2H-indazole-7-carboxamide substantially free of Form II and Form III of 2- ⁇ 4-[(3S)- piperidin-3-yl]phenyl ⁇ -2H-indazole-7-carboxamide, and at least one pharmaceutically acceptable excipient.
- composition of any one of paragraphs [00133]-[00188], wherein the composition is in an oral dosage form.
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG11201909011P SG11201909011PA (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions |
AU2018246214A AU2018246214B2 (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions |
CN201880033357.6A CN110944638A (en) | 2017-03-27 | 2018-03-27 | Nilaparib compositions |
KR1020197031668A KR20200014736A (en) | 2017-03-27 | 2018-03-27 | Nirapap composition |
EP18774912.2A EP3600314A1 (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions |
CA3058375A CA3058375A1 (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions |
JP2019553055A JP2020512350A (en) | 2017-03-27 | 2018-03-27 | Nilaparib composition |
BR112019020211A BR112019020211A2 (en) | 2017-03-27 | 2018-03-27 | niraparib compositions |
MX2019011496A MX2019011496A (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions. |
EA201992177A EA201992177A1 (en) | 2017-03-27 | 2018-03-27 | COMPOSITIONS BASED ON NIRAPARIB |
IL26963019A IL269630A (en) | 2017-03-27 | 2019-09-25 | Niraparib formulations |
US16/584,401 US11091459B2 (en) | 2017-03-27 | 2019-09-26 | Niraparib compositions |
US17/339,896 US11673877B2 (en) | 2017-03-27 | 2021-06-04 | Niraparib compositions |
AU2021245223A AU2021245223A1 (en) | 2017-03-27 | 2021-10-08 | Niraparib compositions |
US18/310,238 US20230416223A1 (en) | 2017-03-27 | 2023-05-01 | Niraparib Compositions |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762477411P | 2017-03-27 | 2017-03-27 | |
US62/477,411 | 2017-03-27 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/584,401 Continuation US11091459B2 (en) | 2017-03-27 | 2019-09-26 | Niraparib compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018183354A1 true WO2018183354A1 (en) | 2018-10-04 |
Family
ID=63676949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/024603 WO2018183354A1 (en) | 2017-03-27 | 2018-03-27 | Niraparib compositions |
Country Status (14)
Country | Link |
---|---|
US (3) | US11091459B2 (en) |
EP (1) | EP3600314A1 (en) |
JP (1) | JP2020512350A (en) |
KR (1) | KR20200014736A (en) |
CN (1) | CN110944638A (en) |
AU (2) | AU2018246214B2 (en) |
BR (1) | BR112019020211A2 (en) |
CA (1) | CA3058375A1 (en) |
EA (1) | EA201992177A1 (en) |
IL (1) | IL269630A (en) |
MX (1) | MX2019011496A (en) |
SG (1) | SG11201909011PA (en) |
TW (1) | TWI761476B (en) |
WO (1) | WO2018183354A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019152989A1 (en) | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
US20200017462A1 (en) | 2017-03-27 | 2020-01-16 | Tesaro, Inc. | Niraparib compositions |
WO2020072860A1 (en) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
WO2021224471A1 (en) | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Pharmaceutical formulations of abiraterone acetate and niraparib |
US11236066B2 (en) | 2019-07-16 | 2022-02-01 | Apotex Inc. | Crystalline forms of niraparib tosylate |
WO2023001746A1 (en) | 2021-07-19 | 2023-01-26 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
US11730725B2 (en) | 2017-09-26 | 2023-08-22 | Tesaro, Inc. | Niraparib formulations |
WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11161834B2 (en) | 2017-04-24 | 2021-11-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
CN110913911A (en) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | Combination therapy for the treatment of cancer |
WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
EA202090655A1 (en) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | COMBINED THERAPEUTIC AGENTS AND THEIR APPLICATION |
WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
WO2023233295A1 (en) | 2022-06-01 | 2023-12-07 | Ideaya Biosciences, Inc. | Thiadiazolyl derivatives as dna polymerase theta inhibitors and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009087381A1 (en) * | 2008-01-08 | 2009-07-16 | Merck Sharp & Dohme Ltd | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
US20100286157A1 (en) * | 2007-10-17 | 2010-11-11 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one |
US20120214998A1 (en) * | 2009-08-26 | 2012-08-23 | Cephalon, Inc. | Novel forms of a multicyclic compound |
CN106496187A (en) * | 2016-09-14 | 2017-03-15 | 陕西科技大学 | A kind of synthetic method for preparing PARP inhibitor Niraparib |
WO2018005818A1 (en) * | 2016-06-29 | 2018-01-04 | Tesaro, Inc. | Methods of treating ovarian cancer |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0606663D0 (en) | 2006-04-03 | 2006-05-10 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
AU2007232297B2 (en) | 2006-04-03 | 2012-09-20 | Msd Italia S.R.L. | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors |
WO2008043024A2 (en) | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
PL2109608T3 (en) * | 2007-01-10 | 2011-08-31 | Msd Italia Srl | Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors |
US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
US9580407B2 (en) | 2012-12-07 | 2017-02-28 | Merck Sharp & Dohme Corp. | Regioselective N-2 arylation of indazoles |
DK2928865T3 (en) | 2012-12-07 | 2018-06-18 | Merck Sharp & Dohme | BIOCATALYTIC TRANSAMINATION PROCEDURE |
JP2016519684A (en) | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | Methods and compositions for improving the efficacy of suboptimally administered medication and / or reducing side effects |
US9191894B2 (en) * | 2013-07-23 | 2015-11-17 | Disney Enterprises, Inc. | Power saving for multi-hop communications |
EP3089965B1 (en) | 2014-01-05 | 2018-08-29 | Washington University | Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor |
EP3134088B1 (en) | 2014-04-22 | 2019-04-10 | Calitor Sciences, LLC | Bicylcic pyrazolone compounds and methods of use |
EP3148336B1 (en) | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
US9987285B2 (en) | 2014-08-22 | 2018-06-05 | Clovis Oncology, Inc. | High dosage strength tablets of rucaparib |
EP3230472A4 (en) | 2014-12-08 | 2018-06-13 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
LT3317281T (en) | 2015-07-02 | 2020-07-27 | Acerta Pharma B.V. | Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
CN106831708A (en) | 2016-11-22 | 2017-06-13 | 西安泰科迈医药科技股份有限公司 | A kind of synthetic method of new oral cancer therapy drug Nirapairb |
CN108201537A (en) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | A kind of Ni Lapani sustained and controlled release medicaments composition and application thereof |
CN106854176A (en) | 2016-12-21 | 2017-06-16 | 南京艾德凯腾生物医药有限责任公司 | A kind of method for preparing Ni Lapani tosilate monohydrates |
WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
CA3058375A1 (en) | 2017-03-27 | 2018-10-04 | Tesaro, Inc. | Niraparib compositions |
TW201842908A (en) | 2017-03-27 | 2018-12-16 | 美商提薩羅有限公司 | Niraparib formulations |
US11161834B2 (en) | 2017-04-24 | 2021-11-02 | Tesaro, Inc. | Methods of manufacturing of niraparib |
KR20200018436A (en) | 2017-05-09 | 2020-02-19 | 테사로, 인코포레이티드 | Combination Therapy for Cancer Treatment |
CN110913911A (en) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | Combination therapy for the treatment of cancer |
CN108530425A (en) | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | A kind of Ni Lapani tosilate hydrate crystal forms and preparation method thereof |
EA202090573A1 (en) | 2017-09-26 | 2020-09-07 | Тесаро, Инк. | COMPOSITIONS OF NIRAPARIBA |
WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | Combination therapies for treating cancer |
EA202090655A1 (en) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | COMBINED THERAPEUTIC AGENTS AND THEIR APPLICATION |
BR112020013214A2 (en) | 2017-12-27 | 2020-12-01 | Tesaro, Inc. | methods to treat cancer |
BR112020015909A2 (en) | 2018-02-05 | 2020-12-15 | Tesaro, Inc. | PEDIATRIC FORMULATIONS OF NIRAPARIB AND PEDIATRIC TREATMENT METHODS |
-
2018
- 2018-03-27 CA CA3058375A patent/CA3058375A1/en active Pending
- 2018-03-27 EA EA201992177A patent/EA201992177A1/en unknown
- 2018-03-27 JP JP2019553055A patent/JP2020512350A/en active Pending
- 2018-03-27 TW TW107110575A patent/TWI761476B/en active
- 2018-03-27 SG SG11201909011P patent/SG11201909011PA/en unknown
- 2018-03-27 KR KR1020197031668A patent/KR20200014736A/en not_active Application Discontinuation
- 2018-03-27 CN CN201880033357.6A patent/CN110944638A/en active Pending
- 2018-03-27 EP EP18774912.2A patent/EP3600314A1/en not_active Withdrawn
- 2018-03-27 WO PCT/US2018/024603 patent/WO2018183354A1/en active Application Filing
- 2018-03-27 BR BR112019020211A patent/BR112019020211A2/en not_active Application Discontinuation
- 2018-03-27 MX MX2019011496A patent/MX2019011496A/en unknown
- 2018-03-27 AU AU2018246214A patent/AU2018246214B2/en active Active
-
2019
- 2019-09-25 IL IL26963019A patent/IL269630A/en unknown
- 2019-09-26 US US16/584,401 patent/US11091459B2/en active Active
-
2021
- 2021-06-04 US US17/339,896 patent/US11673877B2/en active Active
- 2021-10-08 AU AU2021245223A patent/AU2021245223A1/en not_active Abandoned
-
2023
- 2023-05-01 US US18/310,238 patent/US20230416223A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100286157A1 (en) * | 2007-10-17 | 2010-11-11 | Kudos Pharmaceuticals Limited | 4- [3- (4-cyclopropanecarbonyl-piperazine-i-carbonyl) -4 -fluoro-benzyl] -2h-phthalaz in-1-one |
WO2009087381A1 (en) * | 2008-01-08 | 2009-07-16 | Merck Sharp & Dohme Ltd | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
US20120214998A1 (en) * | 2009-08-26 | 2012-08-23 | Cephalon, Inc. | Novel forms of a multicyclic compound |
WO2018005818A1 (en) * | 2016-06-29 | 2018-01-04 | Tesaro, Inc. | Methods of treating ovarian cancer |
CN106496187A (en) * | 2016-09-14 | 2017-03-15 | 陕西科技大学 | A kind of synthetic method for preparing PARP inhibitor Niraparib |
Non-Patent Citations (1)
Title |
---|
JONES, P ET AL.: "Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl)-2H-indazole-7-carboxamide ( MK -4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 52, no. 22, 29 October 2009 (2009-10-29), pages 7170 - 7185, XP055263725, DOI: doi:10.1021/jm901188v * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200017462A1 (en) | 2017-03-27 | 2020-01-16 | Tesaro, Inc. | Niraparib compositions |
US11673877B2 (en) | 2017-03-27 | 2023-06-13 | Tesaro, Inc. | Niraparib compositions |
US11091459B2 (en) | 2017-03-27 | 2021-08-17 | Tesaro, Inc. | Niraparib compositions |
US11730725B2 (en) | 2017-09-26 | 2023-08-22 | Tesaro, Inc. | Niraparib formulations |
WO2019152989A1 (en) | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
US11524953B2 (en) | 2018-10-05 | 2022-12-13 | Macfarlan Smith Limited | Niraparib solid state form |
US20210221787A1 (en) * | 2018-10-05 | 2021-07-22 | Johnson Matthey Public Limited Company | Niraparib solid state form |
WO2020072860A1 (en) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
US11236066B2 (en) | 2019-07-16 | 2022-02-01 | Apotex Inc. | Crystalline forms of niraparib tosylate |
WO2021224469A1 (en) | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Treatments of prostate cancer with combinations of abiraterone acetate and niraparib |
WO2021224467A1 (en) | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Treatment of prostate cancer with a combination of abiraterone acetate and niraparib |
WO2021224471A1 (en) | 2020-05-08 | 2021-11-11 | Janssen Pharmaceutica Nv | Pharmaceutical formulations of abiraterone acetate and niraparib |
CN115515583A (en) * | 2020-05-08 | 2022-12-23 | 詹森药业有限公司 | Pharmaceutical formulations of abiraterone acetate and nilapanib acetate |
WO2023001746A1 (en) | 2021-07-19 | 2023-01-26 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
Also Published As
Publication number | Publication date |
---|---|
AU2021245223A1 (en) | 2021-11-04 |
MX2019011496A (en) | 2020-01-23 |
KR20200014736A (en) | 2020-02-11 |
US11673877B2 (en) | 2023-06-13 |
US20230416223A1 (en) | 2023-12-28 |
IL269630A (en) | 2019-11-28 |
AU2018246214B2 (en) | 2021-07-08 |
BR112019020211A2 (en) | 2020-04-22 |
US20210403448A1 (en) | 2021-12-30 |
US20200017462A1 (en) | 2020-01-16 |
CA3058375A1 (en) | 2018-10-04 |
JP2020512350A (en) | 2020-04-23 |
EA201992177A1 (en) | 2020-02-25 |
AU2018246214A1 (en) | 2019-11-07 |
TWI761476B (en) | 2022-04-21 |
CN110944638A (en) | 2020-03-31 |
US11091459B2 (en) | 2021-08-17 |
EP3600314A1 (en) | 2020-02-05 |
TW201840315A (en) | 2018-11-16 |
SG11201909011PA (en) | 2019-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11673877B2 (en) | Niraparib compositions | |
KR102116087B1 (en) | Oral dosage forms comprising licarbazepine acetate | |
US20240082231A1 (en) | Niraparib formulations | |
JP5514249B2 (en) | Anti-dementia drug stabilization method | |
EP2200599B1 (en) | 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss | |
JP2016053094A (en) | Oral dispersion formulation | |
US20110217369A1 (en) | Fenofibrate compositions | |
US20060034911A1 (en) | New oral immediated release dosage form | |
EP2976067B1 (en) | Pharmaceutical composition comprising a fluoroquinolone antibacterial agent and method for the preparation thereof | |
BRPI0617184A2 (en) | delayed-release pralnacasan formulation | |
KR101506627B1 (en) | Sustained-release pharmaceutical composition comprising acebrophylline and a hydrophilic material | |
TW202327588A (en) | Methods of treating glioblastoma | |
RU2452476C2 (en) | 1-aminoalkylcyclohexane derivatives for treating and preventing hearing loss |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18774912 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2019553055 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 122021026763 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 3058375 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112019020211 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20197031668 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018774912 Country of ref document: EP Effective date: 20191028 |
|
ENP | Entry into the national phase |
Ref document number: 2018246214 Country of ref document: AU Date of ref document: 20180327 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112019020211 Country of ref document: BR Kind code of ref document: A2 Effective date: 20190926 |